DE69334159D1 - Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen - Google Patents

Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen

Info

Publication number
DE69334159D1
DE69334159D1 DE69334159T DE69334159T DE69334159D1 DE 69334159 D1 DE69334159 D1 DE 69334159D1 DE 69334159 T DE69334159 T DE 69334159T DE 69334159 T DE69334159 T DE 69334159T DE 69334159 D1 DE69334159 D1 DE 69334159D1
Authority
DE
Germany
Prior art keywords
met
antibody
hgf
extracellular domain
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69334159T
Other languages
English (en)
Inventor
Donna L Faletto
Ilan Tsarfaty
Sing Rong
Marianne Oskarsson
Woude George F Vande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69334159D1 publication Critical patent/DE69334159D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69334159T 1992-09-18 1993-09-15 Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen Expired - Lifetime DE69334159D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94606192A 1992-09-18 1992-09-18

Publications (1)

Publication Number Publication Date
DE69334159D1 true DE69334159D1 (de) 2007-09-13

Family

ID=25483898

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69334159T Expired - Lifetime DE69334159D1 (de) 1992-09-18 1993-09-15 Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen
DE69315440T Expired - Fee Related DE69315440T2 (de) 1992-09-18 1993-09-15 Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69315440T Expired - Fee Related DE69315440T2 (de) 1992-09-18 1993-09-15 Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie

Country Status (10)

Country Link
EP (2) EP0805203B1 (de)
JP (2) JP3553936B2 (de)
AT (2) ATE368738T1 (de)
AU (1) AU675968B2 (de)
CA (1) CA2144856A1 (de)
DE (2) DE69334159D1 (de)
DK (1) DK0662130T3 (de)
ES (1) ES2112997T3 (de)
GR (1) GR3026165T3 (de)
WO (1) WO1994006909A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
EP0661993B1 (de) * 1992-09-16 1997-05-07 Genentech, Inc. Schutz gegen leberschäden mit hgf
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6855685B2 (en) 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
WO1998019696A1 (en) * 1996-11-05 1998-05-14 Smithkline Beecham Corporation Hepatocyte growth factor antagonists
WO2000025727A2 (en) * 1998-11-04 2000-05-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of flumethasone, fluocinolone acetonide fluoromethasone for manufacture of a medicament for the treatment of tumours
IL131142A0 (en) * 1999-07-28 2001-01-28 Rad Ramot Prognosis of breast cancer and other diseases
AU1598801A (en) * 1999-11-09 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The HGF-SF monoclonal antibody combinations
AU7785401A (en) * 2000-06-29 2002-01-14 Long Island Jewish Res Inst Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
EP1592713A2 (de) * 2003-02-13 2005-11-09 Pharmacia Corporation Antikörper gegen c-met zur behandlung von krebs
SI1648998T1 (sl) 2003-07-18 2015-01-30 Amgen Inc. Specifiäťna vezavna sredstva na hepatocitni rastni faktor
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
ZA200701656B (en) 2004-08-05 2008-09-25 Genentech Inc Humanized anti-cment antagonists
PL1863519T3 (pl) 2005-03-31 2014-03-31 Massachusetts Gen Hospital Modulowanie aktywności HGF/HGFR do leczenia obrzęku wskutek niedrożności naczyń chłonnych
ZA200710599B (en) 2005-04-15 2009-08-26 Genentech Inc HGF Beta chain variants
ATE517126T1 (de) 2006-03-20 2011-08-15 Seikagaku Kogyo Co Ltd Therapeutikum für rheumatoide arthritis
BRPI0709917A2 (pt) 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
CN107739407B (zh) 2010-03-10 2021-07-06 根马布股份公司 抗c-MEt的单克隆抗体
ES2594493T3 (es) 2010-11-03 2016-12-20 arGEN-X BV Anticuerpos anti-c-Met
US9150613B2 (en) 2011-04-02 2015-10-06 Washington State University Hepatocyte growth factor mimics as therapeutic agents
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
BR112017005202A2 (pt) 2014-09-16 2017-12-12 Symphogen As anticorpos anti-met e composições

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US5648273A (en) * 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
GB9003621D0 (en) * 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
CA2091700C (en) * 1990-09-14 2002-11-19 Jeffrey S. Rubin A non-mitogenic competitive hgf antagonist
ATE222603T1 (de) * 1992-05-18 2002-09-15 Genentech Inc Hepatozytwachstumfaktor variante

Also Published As

Publication number Publication date
EP0662130B1 (de) 1997-11-26
EP0805203A1 (de) 1997-11-05
ATE368738T1 (de) 2007-08-15
JPH08504093A (ja) 1996-05-07
WO1994006909A3 (en) 1994-05-26
AU4855593A (en) 1994-04-12
AU675968B2 (en) 1997-02-27
JP2004002440A (ja) 2004-01-08
DE69315440D1 (de) 1998-01-08
CA2144856A1 (en) 1994-03-31
EP0805203B1 (de) 2007-08-01
ATE160585T1 (de) 1997-12-15
ES2112997T3 (es) 1998-04-16
JP3553936B2 (ja) 2004-08-11
DE69315440T2 (de) 1998-07-09
GR3026165T3 (en) 1998-05-29
EP0662130A1 (de) 1995-07-12
DK0662130T3 (da) 1998-08-10
WO1994006909A2 (en) 1994-03-31

Similar Documents

Publication Publication Date Title
ATE368738T1 (de) Medizinische verwendung eines antikörpers oder eines antikörperfragments gegen die extrazelluläre domäne von met zur prevention von metastasen
DK1294769T3 (da) Antistoffer der immunspecifikt binder til BLyS
DE69433406D1 (de) Antikörper gegen cd40
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
DK0536275T3 (da) Tumorvækstinhibitorer udledt fra væv, fremgangsmåde til deres fremstilling samt anvendelse heraf
DE68927671D1 (de) Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
ATE236271T1 (de) Verwendung der ndv zur herstellung eines medikaments zur krebsbehandlung
DE69002325T2 (de) Pharmazeutische zusammensetzung zur verhütung oder heilung von durch den papillomavirus induzierten tumoren.
DE69211899D1 (de) Siloxan modifizierter Polyester zur Behandlung von Fasern
ATE194168T1 (de) Varianten in den leltin domäne von selektin
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE69613168T2 (de) Verwendung eines CGRP-Antagonisten zur Behandlung von Lichen und Pruritus und erhaltene Zusammensetzung
GR76280B (de)
DE69006221D1 (de) Verfahren zur behandlung von septischem schock.
EA199800821A1 (ru) Способ лечения аутизма
ATE126704T1 (de) Bcrf1-antagonisten zur behandlung von epstein- barr-virus-infektionen.
DE68901234D1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.

Legal Events

Date Code Title Description
8332 No legal effect for de